Phase II Study of Subcutaneous Inj. Depot of Octreotide in Patients With Acromegaly and Neuroendocrine Tumours (NETs)

NCT02299089 · clinicaltrials.gov ↗

PHASE2

Phase

COMPLETED

Status

12

Enrollment

INDUSTRY

Sponsor class

Conditions

Acromegaly
Neuroendocrine Tumors

Interventions

DRUG: octreotide FluidCrystal® injection depot

Sponsor

Camurus AB

Collaborators

[object Object]